Revenue Growth - Q4 2023 net revenues increased by 88% to $26.3 million compared to Q4 2022[7] - Full year 2023 net revenues rose by 49% to $80.8 million compared to 2022[8] - U.S. net revenue for Q4 2023 was $19.2 million, up 104% year-over-year[11] - International net revenue for Q4 2023 reached $7.1 million, a 54% increase from Q4 2022[7] - U.S. net revenue for 2023 increased by 66% to $56.7 million, driven by the acquisition of YUTIQ[13] - International net revenue for 2023 grew by 21% to approximately $24.0 million[8] - Net revenue for the three months ended December 2023 was $26,306,000, up 87.5% from $14,029,000 in the same period of 2022[34] Profitability - Adjusted EBITDA for Q4 2023 was $5.0 million, compared to an adjusted EBITDA loss of $(1.2) million in Q4 2022[17] - The company expects to achieve over $105 million in net revenue for 2024, with an Adjusted EBITDA margin greater than 20%[4] - Full year 2023 net loss was approximately $(20.1) million, compared to $(18.1) million in 2022[8] - Net loss applicable to common shareholders for the twelve months ended December 2023 was $21,391,000, compared to a loss of $18,107,000 in 2022, reflecting a 12.6% increase in losses[34] - Non-GAAP adjusted EBITDA for the three months ended December 2023 was $5,030,000, a significant improvement from a loss of $1,238,000 in the same period of 2022[36] Assets and Liabilities - Total current assets increased to $52,423,000 in December 2023 from $29,413,000 in December 2022, representing a 78.1% growth[31] - Total liabilities rose to $107,355,000 in December 2023 from $63,410,000 in December 2022, marking a 69.2% increase[31] - Total assets increased to $153,524,000 in December 2023 from $42,602,000 in December 2022, reflecting a 260.5% growth[31] - Cash and cash equivalents increased to $12,058,000 in December 2023 from $5,274,000 in December 2022, representing a 128.5% increase[31] Operating Expenses - Operating expenses for the twelve months ended December 2023 totaled $71,849,000, up from $57,949,000 in 2022, indicating a 24% increase[34] Gross Profit - Gross profit for the twelve months ended December 2023 reached $69,917,000, a 51.5% increase compared to $46,152,000 in 2022[34] - The company reported a gross profit margin of 86.1% for the three months ended December 2023, compared to 84.8% in the same period of 2022[34] Management Changes - The company has strengthened its management team with new key appointments[9]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34703 Alimera Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 20-0028718 (State or other jur ...

Alimera Sciences, Inc. (NASDAQ:ALIM) Q3 2023 Results Conference Call October 26, 2023 9:00 AM ET Company Participants Scott Gordon - CORE IR Rick Eiswirth - President, CEO & Director Russell Skibsted - SVP & CFO Conference Call Participants Alex Nowak - Craig-Hallum Yi Chen - H.C. Wainwright Laura Suriel - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. Good morning, and welcome to the Alimera Sciences Third Quarter 2022 [2023] (sic) Financial Results and Corporate Update ...

Alimera Sciences, Inc. (NASDAQ:ALIM) Q2 2023 Earnings Conference Call August 10, 2023 9:00 AM ET Company Participants Scott Gordon - CORE IR Richard Eiswirth - President, CEO & Director Russell Skibsted - SVP & CFO Conference Call Participants Alexander Nowak - Craig-Hallum James Molloy - Alliance Global Partners Yi Chen - H.C. Wainwright & Co. Operator Ladies and gentlemen, thank you for standing by. Good morning, and welcome to the Alimera Sciences Second Quarter 2023 Financial Results Conference Call. [O ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34703 Alimera Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 20-0028718 (State or other jurisdic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34703 Alimera Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 20-0028718 (State or other jurisdi ...

Alimera Sciences, Inc. (NASDAQ:ALIM) Q4 2022 Earnings Conference Call March 31, 2023 9:00 AM ET Company Participants Scott Gordon - CORE, Investor Relations Rick Eiswirth - President & CEO Russell Skibsted - SVP and CFO Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Yi Chen - H.C. Wainwright & Co., LLC Operator Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Sciences 2022 Financial Results Conference Call. At this time, all participants are in a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34703 Alimera Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 20-0028718 (State or other jurisdiction ...

Financial Data and Key Metrics Changes - The company reported revenue of $13.6 million for Q3 2022, an 11% increase compared to Q3 2021, but negatively impacted by currency fluctuations which reduced revenue by approximately $800,000 [6][15] - Year-to-date consolidated net revenues were $40.1 million, representing an 18% growth compared to $34 million in the same period of 2021, with a currency-adjusted growth of 23.5% [6][19] - The adjusted EBITDA loss for Q3 2022 was $2.5 million, compared to a loss of $1.1 million in Q3 2021 [18] Business Line Data and Key Metrics Changes - U.S. segment revenues increased by 27% to $8.9 million in Q3 2022, with end-user demand reaching a record of 1,061 units, up from 837 units in Q3 2021 [7][15] - International segment revenues decreased to $4.7 million, down approximately 10% year-over-year, but currency-adjusted revenue was up 6% [10][16] - End-user demand in the international segment grew 16% year-to-date compared to the prior year [10] Market Data and Key Metrics Changes - The U.S. segment's end-user demand was driven by a focus on face-to-face interactions with customers, resulting in significant growth [7] - The international segment's performance was affected by varying recovery rates across different countries, with expectations for growth in 2023 [10] Company Strategy and Development Direction - The company aims to expand the Challenge '22 program to five sales regions to enhance focus on key accounts and improve collaboration [8] - Strategic growth opportunities include expanding ILUVIEN's use for non-infectious posterior uveitis, with reimbursement obtained in six European countries [11] - The company is committed to rationalizing operating expenses to achieve sustainable positive EBITDA and cash flow [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow-neutral to positive status in 2023, supported by reduced operating expenses [29] - The company anticipates that the ongoing NEW DAY study and upcoming studies will enhance ILUVIEN's visibility and utility in treating retinal diseases [22] Other Important Information - The company plans to limit cash operating expenditures to less than $12 million per quarter in 2023, representing a 15% decrease [19] - The company is working with its lender to address the classification of $21 million in debt as current due to upcoming amortization [36] Q&A Session Summary Question: Risks associated with decreasing investments - Management believes that focusing on face-to-face engagement with physicians will sustain sales growth despite cuts in other areas [25][27] Question: Expectations for cash flow in 2023 - Management expects to achieve cash flow-neutral to positive status in 2023 based on projected expenses and moderate growth [29] Question: Changes in sales force structure - No disruption is expected; the company will maintain the number of territories while increasing regional directors for better focus on key accounts [31] Question: Monthly performance in Q3 - Q3 showed inconsistent performance with strong July and August, followed by a drop in September, attributed to competition from new products [34] Question: Timeline for clinical studies - The DRCR study is anticipated to take two years for enrollment, while the NEW DAY study aims for data availability in 2024 [39]